miRNA as biomarker in lung cancer.


Journal

Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 14 03 2023
accepted: 18 07 2023
medline: 10 11 2023
pubmed: 24 9 2023
entrez: 23 9 2023
Statut: ppublish

Résumé

Lung cancer has a high prevalence and mortality due to its late diagnosis and limited treatment, so it is essential to find biomarkers that allow a faster diagnosis and improve the survival of these patients. In this sense, biomarkers based on miRNAs have supposed a considerable advance. miRNAs, which are small RNA sequences, can regulate gene expression, so they play an essential role not only as a diagnostic biomarker but also as a therapeutic and prognostic one. Also, miRNA biomarkers can be obtained from liquid biopsies, which are less intrusive than lung biopsies, and have better accessibility, safety and repeatability, which allows using those biomarkers both for diagnosis and monitoring of patients. In this review, we highlight the importance of miRNAs and collect the existing evidence of their relationship with lung cancer.

Identifiants

pubmed: 37741809
doi: 10.1007/s11033-023-08695-9
pii: 10.1007/s11033-023-08695-9
pmc: PMC10635960
doi:

Substances chimiques

MicroRNAs 0
Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

9521-9527

Informations de copyright

© 2023. The Author(s).

Références

Crit Rev Oncol Hematol. 2021 May;161:103311
pubmed: 33781866
Lung Cancer. 2017 May;107:100-107
pubmed: 27180141
Cancer Cell. 2006 Mar;9(3):189-98
pubmed: 16530703
Int J Mol Sci. 2020 Jun 27;21(13):
pubmed: 32604993
Curr Pharm Des. 2018 Feb 12;23(39):5997-6010
pubmed: 28714414
Cell Res. 2008 Oct;18(10):997-1006
pubmed: 18766170
J Thorac Dis. 2018 Apr;10(Suppl 7):S876-S881
pubmed: 29780634
Biomed Pharmacother. 2016 Dec;84:123-129
pubmed: 27643554
Int J Cancer. 2010 Dec 15;127(12):2870-8
pubmed: 21351266
Mol Biol Rep. 2023 Feb;50(2):1727-1741
pubmed: 36441373
Curr Oncol. 2016 Apr;23(2):e86-94
pubmed: 27122989
J Clin Med. 2019 Mar 26;8(3):
pubmed: 30917582
JNMA J Nepal Med Assoc. 2020 Jul 31;58(227):519-524
pubmed: 32827019
Int J Mol Sci. 2018 Sep 21;19(10):
pubmed: 30248975
Front Med. 2017 Dec;11(4):522-527
pubmed: 28744793
Cancer Res. 2009 Jul 15;69(14):5776-83
pubmed: 19584273
Mol Aspects Med. 2019 Dec;70:3-20
pubmed: 30102929
Curr Pharm Des. 2018 Feb 12;23(39):5989-5996
pubmed: 28714413

Auteurs

Esperanza Salcedo Lobera (ES)

U.G.C. Medico-Quirurgica de Enfermedades Respiratorias, Hospital Regional Universitario de Malaga, Malaga, Spain.

Macarena Arroyo Varela (MA)

U.G.C. Medico-Quirurgica de Enfermedades Respiratorias, Hospital Regional Universitario de Malaga, Malaga, Spain. macarroyo@gmail.com.

Rafael Larrosa Jimenez (RL)

Department of Computer Architecture, University of Malaga, Malaga, Spain.
Andalusian Platform for Bioinformatics at SCBI, University of Malaga, Malaga, Spain.

Rocio Bautista Moreno (RB)

Andalusian Platform for Bioinformatics at SCBI, University of Malaga, Malaga, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH